183 related articles for article (PubMed ID: 28487044)
1. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
[TBL] [Abstract][Full Text] [Related]
2. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.
Dimou F; Sineshaw H; Parmar AD; Tamirisa NP; Jemal A; Riall TS
J Gastrointest Surg; 2016 Jan; 20(1):93-103; discussion 103. PubMed ID: 26503262
[TBL] [Abstract][Full Text] [Related]
3. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
[TBL] [Abstract][Full Text] [Related]
4. Geographic disparities in surgical treatment recommendation patterns and survival for pancreatic adenocarcinoma.
Salami A; Alvarez NH; Joshi ART
HPB (Oxford); 2017 Nov; 19(11):1008-1015. PubMed ID: 28838634
[TBL] [Abstract][Full Text] [Related]
5. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
[TBL] [Abstract][Full Text] [Related]
6. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
[TBL] [Abstract][Full Text] [Related]
7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
8. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis.
Amin S; Lucas AL; Frucht H
Pancreas; 2013 Mar; 42(2):249-53. PubMed ID: 22836862
[TBL] [Abstract][Full Text] [Related]
9. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
10. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.
Visser BC; Ma Y; Zak Y; Poultsides GA; Norton JA; Rhoads KF
HPB (Oxford); 2012 Aug; 14(8):539-47. PubMed ID: 22762402
[TBL] [Abstract][Full Text] [Related]
11. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
Murphy MM; Simons JP; Ng SC; McDade TP; Smith JK; Shah SA; Zhou Z; Earle CC; Tseng JF
Ann Surg Oncol; 2009 Nov; 16(11):2968-77. PubMed ID: 19669839
[TBL] [Abstract][Full Text] [Related]
12. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
13. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer.
Yang SH; Guo JC; Yeh KH; Tien YW; Cheng AL; Kuo SH
J Gastroenterol Hepatol; 2016 Dec; 31(12):2004-2012. PubMed ID: 27059987
[TBL] [Abstract][Full Text] [Related]
14. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
15. Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.
Burke EE; Marmor S; Portschy PR; Virnig BA; Cho LC; Tuttle TM; Jensen EH
HPB (Oxford); 2015 Jun; 17(6):542-50. PubMed ID: 25726950
[TBL] [Abstract][Full Text] [Related]
16. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
17. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.
Shapiro M; Chen Q; Huang Q; Boosalis VA; Yoon CH; Saund MS; Whang EE; Gold JS
JAMA Surg; 2016 Apr; 151(4):338-45. PubMed ID: 26581025
[TBL] [Abstract][Full Text] [Related]
18. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
19. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness.
Krzyzanowska MK; Weeks JC; Earle CC
J Clin Oncol; 2003 Sep; 21(18):3409-14. PubMed ID: 12972517
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma.
Murphy MM; Simons JP; Hill JS; McDade TP; Chau Ng S; Whalen GF; Shah SA; Harrison LH; Tseng JF
Cancer; 2009 Sep; 115(17):3979-90. PubMed ID: 19514091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
